Mylan N.V. (MYL) is expected to report earnings of $1.35 a share on sales of $3.1 billion after the market closes Feb. 26, based on a FactSet survey of 16 analysts.
In the same period a year ago, the pharmaceutical developer posted earnings of $1.43 a share on sales of $3.2 billion.
The stock has fallen 0.4% since the company last reported earnings on Nov. 5.
Quarterly estimates have fallen 2.9 cents a share in the past month.
Mylan is currently trading at a price-to-forward-earnings ratio of 6.2 based on the 12-month estimates of 17 analysts surveyed by FactSet.